Tag: Rexahn Pharma

Finance

Micro-cap Active runners: CytRx Corporation (NASDAQ:CYTR), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Rexahn Pharmaceuticals (NYSEMKT:RNN)

CytRx Corporation (NASDAQ:CYTR) seeks to present the detailed results of the positive outcome from the study which was conducted in an animal representation of glioblastoma at the AACRAM which will be held from between April 5 and April 9 in San Diego, CA. CytRx Corporation (NASDAQ:CYTR) stock performance was 3.67% in last session and finished the day at $3.95. Traded volume was 11.77million shares in … Continue reading Micro-cap Active runners: CytRx Corporation (NASDAQ:CYTR), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Rexahn Pharmaceuticals (NYSEMKT:RNN)

Mark DeFrance
Finance

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Jayne Crisman
Finance

Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference  held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional … Continue reading Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox
BioTech

Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $795.32million. After announcing two years ago that it would … Continue reading Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Richard Atkins